Patent ID: 8846664

Claim:
A compound of Formula I: or a tautomer or pharmaceutically acceptable salt thereof, wherein W 1 represents an aryl, a 3- to 8-membered carbocyclyl, a 5-, 6- or 7-membered heterocyclic or heteroaryl ring comprising carbon atoms and 1-4 heteroatoms independently selected from O, N, P(O) and S(O) r and W 1 is optionally substituted with 1-5 R a groups; W 2 represents an aryl or a 5- or 6-membered heteroaryl ring comprising carbon atoms and 1-3 heteroatoms independently selected from O, N, P(O) and S(O) r , and W 2 is optionally substituted with 1-5 R b groups; Q is N; L 1 and L 2 are independently selected from a bond, C 1-6 -alkyl, O—C 0-6 -alkyl, NR 1 —C 0-6 -alkyl, C(O)NR 1 —C 0-6 -alkyl, NR 1 C(O)—C 0-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 0-6 -alkyl-S(O) r , C 0-6 -alkyl-S(O) 2 NR 1 , C 0-6 -alkyl-NR 1 S(O) 2 , C(O)—C 0-6 -alkyl, OC(O)NR 1 —C 0-6 -alkyl, NR 1 C(O)O—C 0-6 -alkyl, NR 1 C(O)NR 1 —C 0-6 -alkyl; and the linkers L 1 and L 2 can be included in either direction; R a and R b are independently selected from halo, —CN, —NO 2 , —R 1 , —OR 2 , —O—NR 1 R 2 , —NR 1 R 2 , —NR 1 —NR 1 R 2 , —NR 1 —OR 2 , —C(O)YR 2 , —OC(O)YR 2 , —NR 1 C(O)YR 2 , —SC(O)YR 2 , —NR 1 C(═S)YR 2 , OC(═S)YR 2 , —C(═S)YR 2 , —YC(═NR 1 )YR 2 , —YC(═N—OR 1 )YR 2 , —YC(═N—NR 1 R 2 )YR 2 , —YP(═O)(YR 3 )(YR 3 ), —Si(R 3 ) 3 , —NR 1 SO 2 R 2 , —S(O) r R 2 , —SO 2 NR 1 R 2 and —NR 1 SO 2 NR 1 R 2 ; alternatively two adjacent R a or two adjacent R b groups form with the atoms to which they are attached, a 5-, 6- or 7-membered saturated, partially saturated or unsaturated ring, which is optionally substituted and which contains 0-3 heteroatoms selected from N, O, P(O) and S(O) r ; each Y is independently a bond, —O—, —S— or —NR 1 —; r is 0, 1 or 2; n is 1 or 2; each occurrence of R 1 and R 2 is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic and heteroaryl; each occurrence of R 3 is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic and heteroaryl; alternatively, each NR 1 R 2 moiety is a 5-, 6- or 7-membered saturated, partially saturated or unsaturated ring, which is optionally substituted and which contains 0-2 additional heteroatoms selected from N, O, P(O) and S(O) r ; and each of the foregoing alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl and heterocyclic moiety is optionally substituted.